Seattle, Washington 98109

  • Melanoma (Skin)


RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I/II trial to study the effectiveness of biological therapy in treating patients who have metastatic melanoma.

Study summary:

OBJECTIVES: - Assess the safety and toxicity of cellular adoptive immunotherapy using autologous CD8+ antigen-specific T-cell clones in patients with metastatic melanoma. - Estimate the duration of in vivo persistence of adoptively transferred CD8+ antigen-specific cytotoxic T-cell clones in these patients. - Evaluate the antitumor effects of CD8+ antigen-specific T-cell clones in these patients. OUTLINE: Autologous peripheral blood mononuclear cells are harvested and then CD8+ cytotoxic T-lymphocyte (CTL) clones targeting melanosomal antigens are generated ex vivo. Patients receive cellular adoptive immunotherapy comprising autologous CD8+ CTL clones over 30 minutes on day 1. Patients also receive interleukin-2 subcutaneously every 12 hours on days 1-14 of courses 2-3. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients are followed for approximately 1 year after the last infusion. PROJECTED ACCRUAL: Approximately 20 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Histopathologically proven metastatic melanoma - No CNS metastases - HLA-A2 positive - Bidimensionally measurable disease by palpation on clinical exam or radiographic imaging (x-ray, CT scan, or MRI) - Surgically accessible site for tumor cell procurement (skin, subcutaneous nodule, or superficial node) and patient clinically eligible for such surgery PATIENT CHARACTERISTICS: Age - 18 to 75 Performance status - Karnofsky 80-100% Life expectancy - More than 16 weeks Hematopoietic - WBC greater than 4,000/mm^3 - Absolute neutrophil count greater than 2,000/mm^3 - Platelet count greater than 100,000/mm^3 - Hematocrit greater than 30% Hepatic - Bilirubin no greater than 1.6 mg/dL - SGOT no greater than 150 IU (or no greater than 3 times normal) - Prothrombin time no greater than 1.5 times control Renal - Creatinine no greater than 2.0 mg/dL - Calcium no greater than 12 mg/dL Cardiovascular - No congestive heart failure - No clinically significant hypotension - No symptoms of coronary artery disease - No arrhythmia on EKG requiring drug therapy Pulmonary - No severe chronic obstructive pulmonary disease - FEV_1 at least 1.0 L - DLCO at least 45% of predicted Other - No active infection or oral temperature greater than 38.2 degrees C within 72 hours of study - No systemic infection requiring chronic maintenance or suppressive therapy - HIV negative - No history of seizures - No retinitis or choroiditis - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use adequate contraception - Peripheral blood samples available weekly for 4 consecutive weeks PRIOR CONCURRENT THERAPY: Biologic therapy - At least 4 weeks since other prior immunotherapy Chemotherapy - 1 or 2 courses of cytoreductive chemotherapy allowed for bulky disease - At least 4 weeks since prior standard or investigational chemotherapy Endocrine therapy - At least 4 weeks since prior steroid therapy Radiotherapy - At least 4 weeks since prior radiotherapy Surgery - Not specified Other - At least 4 weeks since other prior investigational drug therapy and recovered



Primary Contact:

Study Chair
Cassian Yee, MD
Fred Hutchinson Cancer Research Center

Backup Contact:


Location Contact:

Seattle, Washington 98109
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 20, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.